New research published in the International Journal of Pharmaceuticals shows that "good" bacteria in the living probiotic Symprove TM can…
New research published in the International Journal of Pharmaceuticals shows that “good” bacteria in the living probiotic Symprove TM can successfully reach and colonize the intestines where they continue to change the existing intestinal flora . They can also modify the immune response.
Researchers found that all bacteria in Symprove survived the stomach to reach and colonize the intestines. The activity of the bacteria in this study was observed using a new human intestinal microbial ecosystem (SHIME) simulator, using donor bacteria from healthy humans. This allows researchers to carefully monitor bacteria by in vitro simulation of humans without the need for invasive procedures and measurements.
The bacteria in Symprove were tested to see if their colonization would help feed the intestinal microbiomy through the production of lactate. The microbiome has been identified as a disease modifier and an essential part of immunity.
Simon Gaisford, Ph.D. professor at University College London says: “We have been able to show that delivery of viable and active bacteria to the stomach affects healthy bacteria in our bodies in a way we have not seen before. The diversity in the donor microbiotics changed clearly For the better and more important, the effect was repeated weekly. We saw that the addition of Symprove reduced inflammatory markers and elevated butyrate levels. If we can make a healthy microbiological healthier, the potential to improve dysbiosis conditions is incredibly exciting. “
The addition of probiotics In the Symprove to the microbiotics of healthy human donors, the proportion of bacterial groups in intestinal flora, which generated a significant increase in butyrate ̵
1; a short-chain fatty acid (SCFA) critical to health and well-being.
Addition of Symprove also inc reacted the antiinflammatory cytokines IL-6 and IL-10, while reducing the inflammatory chemokines IL-8, MCP-1 and CXCL10 associated with inflammatory states and viral infections. The data showed that the feeding of the microbiome results in changes in the intestinal flora as well as a positive anti-inflammatory and immunomodulatory effect.
An increased abundance in beneficial bacteria such as firmicutes and actinobacteria was also observed after the addition of Symprove bacteria in the simulation containers. A lack of these bacteria in the intestine is associated with several health conditions, including irritable bowel syndrome.
“As more research looks at the microbiomy and its relation to public health, the positive effect of specialized water-based probiotics will be more. The data suggest that the greatest advantage of probiotics is their ability to support the existing microbiology flora to help to balance it, “says Barry Smith, Symprove Limited, founder and chairman. “Our research in the last 20 years has pushed to understand more about the microbiomic and the essential role it plays in our overall health. This new study shows how living and active probiotics can have on the body beyond the stomach. It’s incredibly exciting leading academics recognize the effect of feeding the microbiome. We all have a microbiome, and in many cases we only need to help the bacteria already there. “
https: // www. symprove.com/